GlassScriptPhysician profile
Walter K Meeker
NPI 1295727774
$10,622.56
in general payments reported to CMS, 2019-2025
53 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,226 · 2020: $835 · 2021: $1,310 · 2022: $1,651 · 2023: $1,752 · 2024: $1,985 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,594 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,593.51 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,384.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,192.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,037.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $656.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $630.07 | 2019-2025 | Jardiance, Ofev |
| Corium, LLC | $495.33 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $479.22 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Lilly USA, LLC | $420.18 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $396.14 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Amgen INC. | $328.84 | 2019-2025 | Evenity, Prolia, Repatha |
| Ironshore Pharmaceuticals INC. | $295.48 | 2019-2024 | Jornay Pm |
| Dexcom, INC. | $275.20 | 2021-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $219.08 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $184.81 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.24 | 2021-2025 | Xifaxan |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Meeker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.